Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)

Published on Sep 1, 2018in Pharmacological Research5.57
· DOI :10.1016/j.phrs.2018.07.016
Paolo Gelosa23
Estimated H-index: 23
Laura Castiglioni10
Estimated H-index: 10
(University of Milan)
+ 4 AuthorsStefano Bellosta26
Estimated H-index: 26
(University of Milan)
Abstract The use of warfarin, the most commonly prescribed oral anticoagulant, is being questioned by clinicians worldwide due to warfarin several limitations (a limited therapeutic window and significant variability in dose-response among individuals, in addition to a potential for drug-drug interactions). Therefore, the need for non-vitamin K antagonist oral anticoagulants (NOACs) with a rapid onset of antithrombotic effects and a predictable pharmacokinetic (PK) and pharmacodynamic (PD) profile led to the approval of five new drugs: the direct factor Xa (F-Xa) inhibitors rivaroxaban, apixaban, edoxaban and betrixaban (newly approved by FDA) and the direct thrombin (factor-IIa) inhibitor dabigatran etexilate. The advantages of NOACs over warfarin are a fixed-dosage, the absence of the need for drug monitoring for changes in anti-coagulation and fewer clinically significant PK and PD drug–drug interactions. NOACs exposure will likely be increased by the administration of strong P-glycoprotein (P-gp) and cytochrome P450 (CYP) 3A4-inhibitors and may increase the risk of bleeds. On the contrary, P-gp inducers could significantly decrease the NOACs plasma concentration with an associated reduction in their anticoagulant effects. This manuscript gives an overview of NOACs PK profiles and their drug-drug interactions potential. This is meant to be of help to physicians in choosing the best therapeutic approach for their patients.
  • References (165)
  • Citations (8)
#1Farhan Shahid (University of Birmingham)H-Index: 4
#2Daniele Pastori (University of Birmingham)H-Index: 20
Last.Gregory Y.H. Lip (University of Birmingham)H-Index: 141
view all 4 authors...
#1Emanuel Raschi (UNIBO: University of Bologna)H-Index: 22
#2Matteo Bianchin (UNIBO: University of Bologna)H-Index: 4
Last.Walter Ageno (University of Insubria)H-Index: 45
view all 5 authors...
Cited By8
#1Emanuel Raschi (UNIBO: University of Bologna)H-Index: 22
#2Matteo Bianchin (UNIBO: University of Bologna)H-Index: 4
Last.Fabrizio De Ponti (UNIBO: University of Bologna)H-Index: 37
view all 5 authors...
#1Matthew M. Bower (UCI: University of California, Irvine)H-Index: 1
#2Alexander J. Sweidan (UCI: University of California, Irvine)H-Index: 2
Last.Wengui Yu (UCI: University of California, Irvine)H-Index: 10
view all 6 authors...
#1Noémie Kraaijpoel (UvA: University of Amsterdam)H-Index: 6
#2Marc Carrier (Ottawa Hospital Research Institute)H-Index: 41
View next paperInteractions between non-vitamin K oral anticoagulants and antiepileptic drugs